Pharmacy Urges US FDA To Disallow Levels Of DMF Solvent It Found In Valsartan
Executive Summary
The saga of tainted valsartan has taken another turn with an online pharmacy that tests its medications before dispensing them finding yet another probable carcinogen in lots of the blood pressure medication from multiple manufacturers. The pharmacy filed a citizen petition asking the US FDA to tighten its globally harmonized limit for the residual solvent.
You may also be interested in...
Cleveland Clinic Drug Quality Dashboard Helps Guide Product Choices
After realizing some generics don’t work, academic medical center screens quality by manufacturer. Other providers protest: It’s not our job.
FDA And EMA Evaluate Claims As Nitrosamine Worries Turn To Zantac
Pharmacy petitions for recalls after finding ‘inherent instability’ in antacid that could pose carcinogenic risk.
Online Pharmacy Stirs Ranitidine Controversy With Petition To Halt Sales
After its tests showed ranitidine forms a nitrosamine impurity that is a probable carcinogen, Valisure asks FDA to suspend sales of antacid products containing the API. In citizen petition firm, online pharmacy also advises FDA to publish regulations requiring independent chemical testing, verification of drugs.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests:
